CURE Pharma Could Take Over Where Zynerba Fell Short

Zynerba Phamaceuticals fall in shares could create a boost for CURE Pharma

Ryan Allway

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) shares fell more than 53% earlier this week after mid-stage clinical trials for its cannabidiol (“CBD”) gel in adult epilepsy patients fell short of primary and secondary endpoints. But, the results could be a boost for competitors, like GW Pharmaceuticals plc (NASDAQ: GWPH) and CURE Pharmaceutical Holding Corp. (OTCQB: CURR), which are developing similar products.

According to Leerink Partners analyst Paul Matteis, GW Pharmaceutical shares have underperformed due to the lack of clear positive catalysts in the backdrop of multiple competitive readouts. The failure of the Zynerba study reinforces the view that barriers to entry for related CBD products are high. These sentiments may also apply for smaller companies in the space, such as CURE Pharma, which is developing its own CBD products.

What’s Different?

CURE Pharma is a relatively new entrant into the pharmaceutical cannabinoid market. In May, the company announced that it had begun researching and developing proprietary formulas consisting of various cannabinoids and terpene profiles integrated into its advanced oral thin film technology, known as CureFilm™. Management has since focused on forming partnerships and collaborations with top healthcare and cannabis industry organizations around the world.

“Our goal is to bring new cannabinoid molecules to market through the FDA regulatory process, while utilizing our company’s proprietary delivery technologies to increase efficacy, as well as target unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options,” said CURE Pharma CEO Rob Davidson.

CureFilm™ leverages a micro-encapsulation process that protects active ingredients to enable higher dosing with better flavor masking. Unlike competing delivery systems, the technology can load multiple active pharmaceutical ingredients – or APIs – onto a single strip. The plan is to leverage the so-called entourage effect of cannabinoids while providing better bioavailability than many competing technologies to maximize safety and efficacy.

Continue reading this article at

Don’t forget to like and subscribe to WeedTV @yourweedtv


#ZynerbaPharmaceuticalsInc #stock CUREPharma